Psychotropic medication prescribing in assisted living and nursing home residents with dementia after the National Partnership.
Alzheimer disease
assisted living facilities
dementia
nursing homes
psychotropic drugs
Journal
Journal of the American Geriatrics Society
ISSN: 1532-5415
Titre abrégé: J Am Geriatr Soc
Pays: United States
ID NLM: 7503062
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
30
06
2022
received:
24
04
2022
accepted:
27
07
2022
pubmed:
20
8
2022
medline:
21
12
2022
entrez:
19
8
2022
Statut:
ppublish
Résumé
The Centers for Medicare & Medicaid Services implemented the National Partnership to Improve Dementia Care in Nursing Homes (the Partnership) to decrease antipsychotic use and improve care for nursing home (NH) residents with dementia. We determined whether the extent of antipsychotic and other psychotropic medication prescribing in AL residents with dementia mirrored that of long-stay NH (LSNH) residents after the Partnership. Using a 20% sample of fee-for-service Medicare beneficiaries with Part D, we conducted a retrospective cohort study including AL and LSNH residents with dementia. The monthly prevalence of psychotropic medication prescribing (antipsychotics, antidepressants, anxiolytics/sedative-hypnotics, anticonvulsants/mood stabilizers, benzodiazepines, and antidementia medications) was examined. We used an interrupted time-series analysis to compare medication prescribing before (July 1, 2010-March 31, 2012) and after (April 1, 2012-December 31, 2017) the Partnership in both settings. We identified 107,931 beneficiaries with ≥1 month as an AL resident and 323,766 beneficiaries with ≥1 month as a LSNH resident with dementia, including 1,923,867 person-months and 4,984,405 person-months, respectively. Antipsychotic prescribing declined over the study period in both settings. After the launch of the Partnership, the rate of decline in antipsychotic prescribing slowed in AL residents with dementia (slope change = 0.03 [95% CLs: 0.02, 0.04]) while the rate of decline in antipsychotic prescribing increased in LSNH residents with dementia (slope change = -0.12 [95% CLs: -0.16, -0.08]). Antidepressants were the most prevalent medication prescribed, anticonvulsant/mood stabilizer prescribing increased, and anxiolytic/sedative-hypnotic and antidementia medication prescribing declined. The federal Partnership to reduce antipsychotic prescribing in NH residents did not appear to affect antipsychotic prescribing in AL residents with dementia. Given the increase in the prescribing of mood stabilizers/anticonvulsants that occurred after the launch of the Partnership, monitoring may be warranted for all psychotropic medications in AL and NH settings.
Sections du résumé
BACKGROUND
The Centers for Medicare & Medicaid Services implemented the National Partnership to Improve Dementia Care in Nursing Homes (the Partnership) to decrease antipsychotic use and improve care for nursing home (NH) residents with dementia. We determined whether the extent of antipsychotic and other psychotropic medication prescribing in AL residents with dementia mirrored that of long-stay NH (LSNH) residents after the Partnership.
METHODS
Using a 20% sample of fee-for-service Medicare beneficiaries with Part D, we conducted a retrospective cohort study including AL and LSNH residents with dementia. The monthly prevalence of psychotropic medication prescribing (antipsychotics, antidepressants, anxiolytics/sedative-hypnotics, anticonvulsants/mood stabilizers, benzodiazepines, and antidementia medications) was examined. We used an interrupted time-series analysis to compare medication prescribing before (July 1, 2010-March 31, 2012) and after (April 1, 2012-December 31, 2017) the Partnership in both settings.
RESULTS
We identified 107,931 beneficiaries with ≥1 month as an AL resident and 323,766 beneficiaries with ≥1 month as a LSNH resident with dementia, including 1,923,867 person-months and 4,984,405 person-months, respectively. Antipsychotic prescribing declined over the study period in both settings. After the launch of the Partnership, the rate of decline in antipsychotic prescribing slowed in AL residents with dementia (slope change = 0.03 [95% CLs: 0.02, 0.04]) while the rate of decline in antipsychotic prescribing increased in LSNH residents with dementia (slope change = -0.12 [95% CLs: -0.16, -0.08]). Antidepressants were the most prevalent medication prescribed, anticonvulsant/mood stabilizer prescribing increased, and anxiolytic/sedative-hypnotic and antidementia medication prescribing declined.
CONCLUSIONS
The federal Partnership to reduce antipsychotic prescribing in NH residents did not appear to affect antipsychotic prescribing in AL residents with dementia. Given the increase in the prescribing of mood stabilizers/anticonvulsants that occurred after the launch of the Partnership, monitoring may be warranted for all psychotropic medications in AL and NH settings.
Identifiants
pubmed: 35984088
doi: 10.1111/jgs.18004
pmc: PMC9771901
mid: NIHMS1828784
doi:
Substances chimiques
Antipsychotic Agents
0
Anticonvulsants
0
Psychotropic Drugs
0
Antidepressive Agents
0
Hypnotics and Sedatives
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
3513-3525Subventions
Organisme : NIA NIH HHS
ID : K08 AG071856
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG027296
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG065722
Pays : United States
Informations de copyright
© 2022 The Authors. Journal of the American Geriatrics Society published by Wiley Periodicals LLC on behalf of The American Geriatrics Society.
Références
J Am Med Dir Assoc. 2021 Sep;22(9):1813-1818.e3
pubmed: 33382990
J Am Med Dir Assoc. 2020 Nov;21(11):1629-1635.e8
pubmed: 32693995
JAMA. 2005 Oct 19;294(15):1934-43
pubmed: 16234500
JAMA Psychiatry. 2015 May;72(5):438-45
pubmed: 25786075
JAMA. 2021 Mar 9;325(10):952-961
pubmed: 33687462
Health Serv Res. 2011 Feb;46(1 Pt 1):120-37
pubmed: 21029090
Health Aff (Millwood). 2021 Sep;40(9):1377-1385
pubmed: 34495716
Am J Geriatr Psychiatry. 2022 Jan;30(1):32-42
pubmed: 34059401
Vital Health Stat 3. 2016 Feb;(38):x-xii; 1-105
pubmed: 27023287
J Gerontol A Biol Sci Med Sci. 2022 Jun 1;77(6):1272-1278
pubmed: 34919685
J Gen Intern Med. 2023 Feb;38(2):294-301
pubmed: 35132546
J Gerontol A Biol Sci Med Sci. 2022 Jun 1;77(6):1261-1271
pubmed: 34919686
Gerontologist. 2022 Feb 09;62(2):169-180
pubmed: 33993241
J Clin Epidemiol. 2011 Jul;64(7):749-59
pubmed: 21208778
Gerontologist. 2015 Apr;55(2):199-209
pubmed: 26035596
Curr Treat Options Psychiatry. 2020 Dec;7(4):489-507
pubmed: 33344107
J Am Med Dir Assoc. 2016 Jul 1;17(7):673.e9-673.e15
pubmed: 27346654
Med Care. 2017 Dec;55(12):1046-1051
pubmed: 29087983
J Am Geriatr Soc. 2022 Dec;70(12):3513-3525
pubmed: 35984088
Med Care. 2018 Feb;56(2):e10-e15
pubmed: 27820597
JAMA Intern Med. 2018 May 1;178(5):640-647
pubmed: 29550856
Health Aff (Millwood). 2014 Apr;33(4):658-66
pubmed: 24711328
Am J Psychiatry. 2022 Aug;179(8):544-552
pubmed: 35615813